



Gilenya[®] (fingolimod) – New warning

- On December 15, 2017, the [FDA approved](#) an update to the *Warnings and Precautions* section of the [Gilenya \(fingolimod\)](#) drug label regarding cutaneous malignancies.
- Gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
- The risk of basal cell carcinoma (BCC) and melanoma is increased in patients treated with Gilenya. In two-year placebo-controlled trials, the incidence of BCC was 2% in patients on Gilenya 0.5 mg and 1% in patients on placebo. Melanoma has been reported with Gilenya in the postmarketing setting.
 - Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.
 - Providers and patients are advised to monitor for suspicious skin lesions. If a suspicious skin lesion is observed, it should be promptly evaluated.
 - As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.
- Revisions were also made to the subsection of the *Warning and Precautions* section regarding progressive multifocal leukoencephalopathy.
- Due to the *Warnings and Precautions* section updates, similar changes were made to the *Patient Counseling* section and the Medication Guide of the Gilenya drug label.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.